文献速递疼痛医学

鞘内药物输注治疗癌症疼痛与症状负担的前后变化:222例混合模型分析

Pain and symptom severity outcomes in patients with cancer before and after intrathecal drug delivery: mixed model analysis in 222 cases.
PubMed 文献 · Reg Anesth Pain Med · 2026-09-08

回顾性分析2013至2023年435例接受鞘内药物输注(IDD)的癌症疼痛患者,222例符合纳入标准。采用联合纵向-生存模型处理死亡导致的脱落,发现植入前症状轨迹恶化,植入后90天内BPI严重度、干扰度及CMSAS生理评分均显著改善,且获益持续至1年。

要点

  • IDD植入后90天内疼痛严重度与干扰度每日显著下降,生理症状负担改善。
  • 植入前疼痛与症状轨迹呈恶化趋势,植入后转为改善并持续至1年。
  • 随访期间91%患者停用全身性阿片类药物。

核心结论

  • 晚期癌症患者在接受IDD前疼痛与症状负担 worsening,植入后90天内改善并持续至1年。

研究设计与样本

  • 回顾性分析2013至2023年单中心435例癌症疼痛IDD患者,222例符合纳入标准(植入前30天内有症状评估且植入后生存>10天)。
  • 使用联合纵向-生存模型估计IDD后1年内BPI-SEV、BPI-INT和CMSAS-PHYS的变化,以处理死亡导致的信息性脱落。

主要发现

  • 植入后前90天,BPI-SEV每日下降0.014单位(n=219;95%CI -0.020至-0.009;p<0.001)。
  • BPI-INT每日下降0.020单位(n=209;95%CI -0.029至-0.011;p<0.001)。
  • CMSAS-PHYS每日改善0.004单位(n=195;95%CI -0.006至-0.001;p=0.002)。
  • 随访期间91%患者停用全身性阿片类药物。

临床怎么用

  • 对于晚期癌症疼痛患者,IDD可作为减少全身阿片类药物用量并改善疼痛与症状负担的选项。
  • 植入后90天内可观察到疼痛与生理症状的持续改善,支持早期评估疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer-related pain is common and difficult to manage, and many patients require opioid therapy with dose-limiting toxicity. As pain progresses, opioid escalation may result in adverse effects and suboptimal analgesia. Intrathecal drug delivery (IDD) provides targeted analgesia and may reduce systemic toxicity. This study evaluated temporal trends in pain and symptom burden before and after IDD initiation. METHODS: Retrospective analysis of longitudinal Brief Pain Inventory (BPI) and Condensed Memorial Symptom Assessment Scale (CMSAS) scores in 435 patients with cancer pain treated with IDD at an academic cancer center between 2013 and 2023. Inclusion required ≥1 symptom assessment within 30 days prior to implantation and survival >10 days postimplant. Primary outcomes were changes in BPI-Severity (BPI-SEV), BPI-Interference (BPI-INT) and CMSAS-Physical (CMSAS-PHYS) after IDD, estimated using joint longitudinal-survival models to account for informative dropout due to death over 1 year. Pre-IDD symptom trajectories were modeled separately. Secondary outcomes included remaining BPI and CMSAS domains assessed at prespecified time points up to 1 year, analyzed descriptively. RESULTS: 222 patients met inclusion criteria. During follow-up, 91% discontinued systemic opioids. In joint models over the first 90 days after implantation, BPI-SEV decreased by 0.014 units/day (n=219; 95% CI -0.020 to -0.009; p<0.001), BPI-INT decreased by 0.020 units/day (n=209; 95% CI -0.029 to -0.011; p<0.001) and CMSAS-PHYS improved by 0.004 units per day (n=195; 95% CI -0.006 to -0.001; p=0.002). Symptom trajectories worsened prior to implantation and improved following IDD initiation. Mean composite scores improved significantly across all time points for BPI-SEV, BPI-INT and CMSAS-PHYS. CONCLUSIONS: Among patients with advanced cancer, pain and symptom burden worsened prior to IDD but improved within 90 days after implantation, with sustained benefits observed up to 1 year.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Odell DW, Sindt JE, McNeal S, et al. Pain and symptom severity outcomes in patients with cancer before and after intrathecal drug delivery: mixed model analysis in 222 cases. Reg Anesth Pain Med. 2026. PMID: 42710941. doi:10.1136/rapm-2026-107984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。